ES2755957T3 - Anticuerpos de tos ferina humanizados y usos de los mismos - Google Patents

Anticuerpos de tos ferina humanizados y usos de los mismos Download PDF

Info

Publication number
ES2755957T3
ES2755957T3 ES15772977T ES15772977T ES2755957T3 ES 2755957 T3 ES2755957 T3 ES 2755957T3 ES 15772977 T ES15772977 T ES 15772977T ES 15772977 T ES15772977 T ES 15772977T ES 2755957 T3 ES2755957 T3 ES 2755957T3
Authority
ES
Spain
Prior art keywords
antibody
approximately
humanized
antibodies
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15772977T
Other languages
English (en)
Spanish (es)
Inventor
Jennifer Maynard
Annalee Nguyen
Eduardo Padlan
Ellen Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
The University of Texas at Austin
Theriva Biologics Inc
Original Assignee
The University of Texas System
Synthetic Biologics Inc
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System, Synthetic Biologics Inc, The University of Texas at Austin filed Critical The University of Texas System
Application granted granted Critical
Publication of ES2755957T3 publication Critical patent/ES2755957T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1225—Gram-negative bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES15772977T 2014-03-31 2015-03-31 Anticuerpos de tos ferina humanizados y usos de los mismos Active ES2755957T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461973141P 2014-03-31 2014-03-31
US201462046403P 2014-09-05 2014-09-05
PCT/US2015/023715 WO2015153685A1 (en) 2014-03-31 2015-03-31 Humanized pertussis antibodies and uses thereof

Publications (1)

Publication Number Publication Date
ES2755957T3 true ES2755957T3 (es) 2020-04-24

Family

ID=54241237

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15772977T Active ES2755957T3 (es) 2014-03-31 2015-03-31 Anticuerpos de tos ferina humanizados y usos de los mismos

Country Status (8)

Country Link
US (3) US9512204B2 (enExample)
EP (1) EP3126385B1 (enExample)
JP (1) JP6588922B2 (enExample)
CN (1) CN106459183B (enExample)
AU (1) AU2015240834B2 (enExample)
CA (1) CA2941152C (enExample)
ES (1) ES2755957T3 (enExample)
WO (1) WO2015153685A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2752396A1 (en) * 2010-09-17 2012-03-17 Board Of Regents, The University Of Texas System Pertussis antibodies and uses thereof
ES2755957T3 (es) * 2014-03-31 2020-04-24 Univ Texas Anticuerpos de tos ferina humanizados y usos de los mismos
JP6805428B2 (ja) * 2014-04-27 2021-01-06 フェイムウェイヴ リミテッド Ｃｅａｃａｍ１に対するヒト化抗体
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
CN107663240B (zh) * 2016-07-29 2021-01-12 中国人民解放军第四军医大学 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
US10538579B2 (en) * 2016-08-15 2020-01-21 Board Of Regents, The University Of Texas System Bispecific pertussis antibodies
WO2018035107A2 (en) * 2016-08-15 2018-02-22 Board Of Regents, The University Of Texas System Stabilized pertussis antibodies with extended half-life
CN119265240A (zh) 2017-10-20 2025-01-07 弗莱德哈钦森癌症中心 用以产生被遗传修饰来表达所选抗体的b细胞的系统和方法
WO2021000886A1 (zh) * 2019-07-01 2021-01-07 苏州康宁杰瑞生物科技有限公司 百日咳毒素结合蛋白
KR20240167591A (ko) * 2023-05-18 2024-11-27 한국과학기술연구원 항-엔도글린 항체 및 이의 용도
CN121800914A (zh) * 2025-11-28 2026-04-07 北京生物制品研究所有限责任公司 特异性结合百日咳毒素的单克隆抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1223529B (it) 1987-12-18 1990-09-19 Sclavo Spa Epitopo immunodominante protettivo contenuto nella subunita' s1 della tossina della pertosse
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US7417133B2 (en) * 2004-02-27 2008-08-26 Institut Pasteur Methods for obtaining thermostable enzymes, DNA polymerase I variants from Thermus aquaticus having new catalytic activities, methods for obtaining the same, and applications of the same
US8445650B2 (en) * 2007-09-25 2013-05-21 Thomas Jefferson University Mutant botulinum neurotoxin serotype A polypeptide and uses thereof
CA2752396A1 (en) 2010-09-17 2012-03-17 Board Of Regents, The University Of Texas System Pertussis antibodies and uses thereof
WO2014160098A2 (en) * 2013-03-13 2014-10-02 Excelimmune, Inc. Bordetella specific human recombinant antibodies and uses thereof
ES2755957T3 (es) * 2014-03-31 2020-04-24 Univ Texas Anticuerpos de tos ferina humanizados y usos de los mismos

Also Published As

Publication number Publication date
US20170066816A1 (en) 2017-03-09
CA2941152C (en) 2023-09-19
WO2015153685A1 (en) 2015-10-08
US10035846B2 (en) 2018-07-31
CN106459183B (zh) 2020-05-19
US20150353628A1 (en) 2015-12-10
US9512204B2 (en) 2016-12-06
CN106459183A (zh) 2017-02-22
JP2017511140A (ja) 2017-04-20
EP3126385A1 (en) 2017-02-08
AU2015240834B2 (en) 2020-02-27
US10526400B2 (en) 2020-01-07
EP3126385A4 (en) 2018-02-21
JP6588922B2 (ja) 2019-10-09
US20180362621A1 (en) 2018-12-20
EP3126385B1 (en) 2019-09-18
AU2015240834A1 (en) 2016-09-15
CA2941152A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
EP3126385B1 (en) Humanized pertussis antibodies and uses thereof
CN114845739B (zh) 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
ES2973425T3 (es) Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del síndrome respiratorio agudo grave (sars-cov-2)
ES2784131T3 (es) Polipéptidos de unión beta del receptor PDGF
ES2965486T3 (es) Formulaciones de anticuerpos anti-C5 de alta concentración
US9951143B2 (en) Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof
ES2757675T3 (es) Anticuerpos para el tratamiento de la infección y enfermedad asociada a Clostridium difficile
ES2566602T3 (es) Anticuerpos anti-ErbB3
ES2892923T3 (es) Proteína de unión a IL-18 (IL-18BP) en enfermedades inflamatorias
ES2349348T3 (es) Anticuerpos neutralizantes de rsv de ultra alta afinidad.
US20210221907A1 (en) Antibodies specific to trophoblast antigen 2 (trop2)
ES2871574T3 (es) Combinación de anticuerpo anti CD19 con un inhibidor de BCL-2 y usos de la misma
ES2703774T3 (es) Tratamiento para la artritis
CN108472372B (zh) 结合不动杆菌的抗体结合剂及其用途
JP2023545382A (ja) 抗体薬物複合体を含む医薬組成物及びその使用
WO2011028961A2 (en) Anti-botulism antibody coformulations
ES2785349T3 (es) Anticuerpos anti-ricina y sus usos
ES3057414T3 (en) Interleukin 5 binding protein dosage regimen
BR112020020787A2 (pt) métodos e composições para o tratamento de febre amarela
US20210332112A1 (en) Stabilized pertussis antibodies with extended half-life
ES2985731T3 (es) Tratamiento de exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica mediante antagonismo de IL-20R
US10538579B2 (en) Bispecific pertussis antibodies
ES2630226T3 (es) Un agente agotador de células B para el tratamiento de la aterosclerosis
WO2014160098A2 (en) Bordetella specific human recombinant antibodies and uses thereof
JP7315259B2 (ja) 百日咳毒素結合タンパク質